OraSure Technologies, Inc. (OSUR) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions.
Analysis Summary
OraSure Technologies, Inc. reported revenue of $115.0M in the most recent fiscal year, growing at a 5-year CAGR of -7.7%.
Trailing-twelve-month margins: gross margin 41.4%, operating margin -44.7%, net margin -43.7%.
At the current price of $3.49, OSUR has negative trailing earnings (P/E not meaningful) and an ROE of -14.73%. Market capitalisation stands at $240M.
Balance sheet quality for OSUR: current ratio of 6.6, net cash position of $186.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $3.49 |
| Market Cap | $240M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.73 |
| EV / EBITDA | -2.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -14.73% |
| Return on Invested Capital | -14.90% |
| Return on Assets | -13.63% |
| Gross Margin | 41.38% |
| Operating Margin | -44.75% |
| Net Margin | -43.70% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 8.88 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OSUR | OraSure Technologies, Inc. | $240M | 0.73 | -14.7% | |
| 0R29.L | Intuitive Surgical, Inc. | $137.6B | 74.97 | 12.01 | 17.8% |
| ISRG | Intuitive Surgical, Inc. | $135.5B | 44.28 | 7.65 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $52.3B | 33.07 | 2.18 | 6.6% |
| BDX | Becton, Dickinson and Company | $50.0B | 55.98 | 2.09 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 22.82 | 5.24 | 23.9% |
| 0KW4.L | ResMed Inc. | $32.5B | |||
| MDLN | Medline Inc. | $27.2B | 37.72 | 2.40 | 10.8% |
Price Performance
| 1 month | -5.95% |
| 3 months | -18.12% |
| Year-to-date | +43.80% |
| 1 year | +5.45% |
| 3 years | -38.19% |
52-Week Range
| 52-week High | $4.58 |
| 52-week Low | $2.08 |
| Avg Volume (90d) | 590K |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 1998-01-08 | $1.6000 | 183.38% |
Related companies: CATX · GNFT · NAUT · NTHI · NYXH · PRE · PROF
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of OSUR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks